BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Stanfield BA, Rider PJF, Caskey J, Del Piero F, Kousoulas KG. Intramuscular vaccination of guinea pigs with the live-attenuated human herpes simplex vaccine VC2 stimulates a transcriptional profile of vaginal Th17 and regulatory Tr1 responses. Vaccine 2018;36:2842-9. [PMID: 29655629 DOI: 10.1016/j.vaccine.2018.03.075] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Sharma D, Sharma S, Akojwar N, Dondulkar A, Yenorkar N, Pandita D, Prasad SK, Dhobi M. An Insight into Current Treatment Strategies, Their Limitations, and Ongoing Developments in Vaccine Technologies against Herpes Simplex Infections. Vaccines 2023;11:206. [DOI: 10.3390/vaccines11020206] [Reference Citation Analysis]
2 Williams DW, Kim RH. Epithelial cells release IL-36α in extracellular vesicles following mechanical damage. Biochemical and Biophysical Research Communications 2022;605:56-62. [DOI: 10.1016/j.bbrc.2022.02.088] [Reference Citation Analysis]
3 Uche IK, Stanfield BA, Rudd JS, Kousoulas KG, Rider PJF. Utility of a Recombinant HSV-1 Vaccine Vector for Personalized Cancer Vaccines. Front Mol Biosci 2022;9:832393. [DOI: 10.3389/fmolb.2022.832393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Krishnan R, Stuart PM. Developments in Vaccination for Herpes Simplex Virus. Front Microbiol 2021;12:798927. [PMID: 34950127 DOI: 10.3389/fmicb.2021.798927] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
5 Nabi R, Lewin AC, Collantes TM, Chouljenko VN, Kousoulas KG. Intramuscular Vaccination With the HSV-1(VC2) Live-Attenuated Vaccine Strain Confers Protection Against Viral Ocular Immunopathogenesis Associated With γδT Cell Intracorneal Infiltration. Front Immunol 2021;12:789454. [PMID: 34868077 DOI: 10.3389/fimmu.2021.789454] [Reference Citation Analysis]
6 Jambunathan N, Clark CM, Musarrat F, Chouljenko VN, Rudd J, Kousoulas KG. Two Sides to Every Story: Herpes Simplex Type-1 Viral Glycoproteins gB, gD, gH/gL, gK, and Cellular Receptors Function as Key Players in Membrane Fusion. Viruses 2021;13:1849. [PMID: 34578430 DOI: 10.3390/v13091849] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Rider PJ, Dulin H, Uche IK, Mcgee MC, Breitenstein B, Tan GS, Huang W, Kousoulas KG, Hai R. A Herpes Simplex Virus Type-1-derived influenza vaccine induces balanced adaptive immune responses and protects mice from lethal influenza virus challenge.. [DOI: 10.1101/2021.08.05.455241] [Reference Citation Analysis]
8 Sahu U, Biswas D, Prajapati VK, Singh AK, Samant M, Khare P. Interleukin-17-A multifaceted cytokine in viral infections. J Cell Physiol 2021. [PMID: 34133758 DOI: 10.1002/jcp.30471] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
9 Wang X, Yi P, Liang Y. The Role of IL-36 in Infectious Diseases: Potential Target for COVID-19? Front Immunol 2021;12:662266. [PMID: 34054828 DOI: 10.3389/fimmu.2021.662266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
10 Uche IK, Fowlkes N, Vu L, Watanabe T, Carossino M, Nabi R, Del Piero F, Rudd JS, Kousoulas KG, Rider PJF. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model. J Virol 2021;95:e01359-20. [PMID: 33177208 DOI: 10.1128/JVI.01359-20] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
11 Aschner CB, Herold BC. Alphaherpesvirus Vaccines. Curr Issues Mol Biol 2021;41:469-508. [PMID: 32963118 DOI: 10.21775/cimb.041.469] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
12 Kim HC, Lee HK. Vaccines against Genital Herpes: Where Are We? Vaccines (Basel) 2020;8:E420. [PMID: 32727077 DOI: 10.3390/vaccines8030420] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
13 McIntosh EDG. Development of vaccines against the sexually transmitted infections gonorrhoea, syphilis, Chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus. Ther Adv Vaccines Immunother 2020;8:2515135520923887. [PMID: 32647779 DOI: 10.1177/2515135520923887] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
14 Naidu SK, Nabi R, Cheemarla NR, Stanfield BA, Rider PJ, Jambunathan N, Chouljenko VN, Carter R, Del Piero F, Langohr I, Kousoulas KG. Intramuscular vaccination of mice with the human herpes simplex virus type-1(HSV-1) VC2 vaccine, but not its parental strain HSV-1(F) confers full protection against lethal ocular HSV-1 (McKrae) pathogenesis. PLoS One 2020;15:e0228252. [PMID: 32027675 DOI: 10.1371/journal.pone.0228252] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
15 Sandgren KJ, Truong NR, Smith JB, Bertram K, Cunningham AL. Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology. Methods Mol Biol 2020;2060:31-56. [PMID: 31617171 DOI: 10.1007/978-1-4939-9814-2_2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
16 Rider PJF, Uche IK, Sweeny L, Kousoulas KG. Anti-viral immunity in the tumor microenvironment: implications for the rational design of herpes simplex virus type 1 oncolytic virotherapy. Curr Clin Microbiol Rep 2019;6:193-9. [PMID: 33344108 DOI: 10.1007/s40588-019-00134-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Wang P, Gamero AM, Jensen LE. IL-36 promotes anti-viral immunity by boosting sensitivity to IFN-α/β in IRF1 dependent and independent manners. Nat Commun 2019;10:4700. [PMID: 31619669 DOI: 10.1038/s41467-019-12318-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
18 Xu XQ, Liu Y, Zhang B, Liu H, Shao DD, Liu JB, Wang X, Zhou LN, Hu WH, Ho WZ. IL-22 suppresses HSV-2 replication in human cervical epithelial cells. Cytokine 2019;123:154776. [PMID: 31344598 DOI: 10.1016/j.cyto.2019.154776] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
19 Truong NR, Smith JB, Sandgren KJ, Cunningham AL. Mechanisms of Immune Control of Mucosal HSV Infection: A Guide to Rational Vaccine Design. Front Immunol 2019;10:373. [PMID: 30894859 DOI: 10.3389/fimmu.2019.00373] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
20 Mcintosh EDG. Development of vaccines against gonorrhoea, syphilis, chlamydia, herpes simplex virus, human immunodeficiency virus and Zika virus. CMAC 2019;21:253-260. [DOI: 10.36488/cmac.2019.4.253-260] [Reference Citation Analysis]
21 Bernstein DI, Pullum DA, Cardin RD, Bravo FJ, Dixon DA, Kousoulas KG. The HSV-1 live attenuated VC2 vaccine provides protection against HSV-2 genital infection in the guinea pig model of genital herpes. Vaccine 2019;37:61-8. [DOI: 10.1016/j.vaccine.2018.11.042] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 6.3] [Reference Citation Analysis]